ISSN: 2320-480X
Manuscript Submission

The Journal of Phytopharmacology 2023; 12(3):152-163 ;   DOI:10.31254/phyto.2023.12303

Research Article

In silico kinase inhibition profiling of BRAF and AKT Signaling in Melanoma Cells with Nuciferine

Veerabhuvaneshwari Veerichetty1 , Iswaryalakshmi Saravanabavan1 , Abiraamasundari Ramapalaniappan2

1. Department of Biotechnology, Kumaraguru College of Technology, Coimbatore, Tamil Nadu, India
2. Spinos Life science and Research Private Limited, Thudiyalur, Tamil Nadu, India

*Author to whom correspondence should be addressed.

Received: 9th April, 2023 / Accepted: 1st June, 2023 / Published : 30th June, 2023

Abstract


The RAS/RAF and PI3K/AKT pathways play a crucial regulatory role and oncogenic mutation of key proteins in these pathways leads to cancer metastasis and chemoresistance. Melanoma is triggered by NRAS and BRAF V600E mutation which causes constitutive activation of the PI3K kinase and BRAF kinase respectively, further leading to oncogenic activation of the AKT kinase and mitogen-activated protein kinase (MAPK). Core regulatory network behind MAPK and AKT cascades interconnect and form feedback loops. This crosstalk between the two pathways plays a vital role in melanoma kinase inhibitor resistance. Nuciferine is found in the plants Nelumbo Nucifera and Nymphaea Caerulea. Nuciferine is the main aporphine alkaloid produced in Nelumbo nucifera. Nuciferine have the best efficiency to remove oxygen free radicals and hydroxyl free radicals. Nuciferine have potent ROS scavenging activity. Nuciferine provokes anti-inflammation, anti-psychotic drug, anti-cancer treatment, and anti-obesity diseases. This in silico analysis results reinforces nuciferine has an effective kinase inhibitor with a potential advantage of evading resistance in melanoma by dual targeting. The residues of the substrate binding pockets were identified using literature search. Molecular docking studies was carried out using AutoDock. Docking studies indicated nuciferine and vemurafenib (reference standard) showed better binding affinity for kinase pockets of Braf V600E, MEK, ERK, PI3K, AKT, mTOR and c-KIT. -7.00Kcal/mol is considered as the cut-off energy for inhibition analysis. Hydrophobic interactions were computed using Biovia. Biovia was used for the graphical representation of protein ligand binding.

Keywords

BRAF, AKT, Kinase inhibitors, Docking, Nuciferine, Vemurafenib, Melanoma


HOW TO CITE THIS ARTICLE

Veerichetty V, Saravanabavan I, Ramapalaniappan A. In silico kinase inhibition profiling of BRAF and AKT Signaling in Melanoma Cells with Nuciferine. J Phytopharmacol 2023; 12(3):152-163. doi: 10.31254/phyto.2023.12303

Creative Commons (CC) License-

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY 4.0) license. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. (http://creativecommons.org/licenses/by/4.0/).

Copyright

Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0.

Technical Support

×